Meyahealth
Home
ENES
HomeGeneticsGeneGNS gene
Back to Gene
GNS gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

GNS gene

The GNS gene provides instructions for an enzyme that breaks down complex sugar molecules within lysosomes, preventing their harmful accumulation.

Normal Function

The GNS gene provides instructions for producing an enzyme called N-acetylglucosamine-6-sulfatase. This enzyme is located in lysosomes, which are compartments within cells that digest and recycle different types of molecules. N-acetylglucosamine-6-sulfatase is involved in the step-wise breakdown of large molecules called glycosaminoglycans (GAGs). GAGs are long strings of linked sugar molecules. To break them down, the enzyme removes a chemical group known as a sulfate from a subset of GAGs called heparan sulfate when the sugar N-acetylglucosamine-6-sulfate is located at the end of the molecule.

Health Conditions Related to Genetic Changes

Mucopolysaccharidosis type III

Mutations in the GNS gene cause mucopolysaccharidosis type IIID (MPS IIID). Most of these mutations change single DNA building blocks (nucleotides) in the gene, which reduce or eliminate the function of N-acetylglucosamine-6-sulfatase.

The lack of this enzyme activity disrupts the breakdown of heparan sulfate. Consequently, partially broken down GAGs accumulate within lysosomes. Researchers believe this accumulation interferes with the functions of other proteins inside the lysosomes and disrupts normal cellular function. It is currently unknown why the buildup of heparan sulfate in MPS IIID primarily affects the central nervous system.

Other Names for This Gene

  • G6S
  • glucosamine-6-sulfatase
  • GNS_HUMAN
  • MGC21274
  • N-acetylglucosamine-6-sulfatase
  • N-acetylglucosamine-6-sulfatase precursor

Frequently Asked Questions

MPS IIID often presents with developmental delay, speech regression, and progressive loss of motor skills. Physical clues include a large head (macrocephaly), coarse facial features, and joint stiffness. Early neurologic changes such as difficulty with balance or coordination can also be warning signs. If these symptoms appear, a pediatrician may recommend a metabolic work‑up and genetic testing for GNS mutations.
MPS IIID follows an autosomal recessive pattern, meaning both parents carry one defective GNS allele. Each child has a 25% chance of being affected if both parents are carriers. Genetic counseling is recommended for families; carrier testing can be done for relatives, and prenatal or pre‑implantation genetic diagnosis is available for future pregnancies.
Confirmation usually starts with a urine test for elevated glycosaminoglycans (GAGs). If GAGs are high, a blood or skin biopsy is performed to measure N‑acetylglucosamine‑6‑sulfatase activity. A definitive diagnosis is made by sequencing the GNS gene to identify pathogenic variants. The test is typically ordered by a metabolic or genetic specialist.
Current therapies focus on managing symptoms and slowing progression. Enzyme replacement therapy (ERT) is not yet approved for MPS IIID, but clinical trials are exploring substrate reduction or gene‑based approaches. Supportive care includes physical therapy, occupational therapy, speech therapy, and monitoring for cardiac or respiratory complications. Early intervention can improve quality of life.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ